This phase II trial studies the side effects of salsalate when added to venetoclax and decitabine or azacitidine in treating patients with acute myeloid leukemia or myelodysplasia/myeloproliferative disease that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and azacitidine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04146038.
PRIMARY OBJECTIVE:
I. Determine the tolerability of the addition of standard dose salsalate to the standard treatment combination of venetoclax + hypomethylating agent (HMA) (decitabine or azacitidine [5-azacytidine]).
SECONDARY OBJECTIVES:
I. Determine the remission rate and, when feasible, perform exploratory studies of:
Ia. Patterns of mutation clearance.
Ib. Distribution of cells with low and high reactive oxygen species (ROS) content at various points during therapy.
OUTLINE:
CYCLE 1: Patients receive salsalate orally (PO) twice daily (BID) until completion of cycle 1. 24-48 hours later or concurrent with salsalate, patients begin to receive decitabine intravenously (IV) for 10 days or azacitidine IV for 7 days. Starting 24 hour after salsalate, patients also receive venetoclax PO continuously until completion of cycle 1.
CYCLE 2: Patients receive decitabine IV for 5 days or azacitidine IV for 7 days, salsalate PO BID, and venetoclax PO continuously.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Lead OrganizationRutgers Cancer Institute of New Jersey
Principal InvestigatorRoger Kurt Strair
